These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 8750153)
21. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray. Choi DH; Kim S; Rimm DL; Carter D; Haffty BG Cancer J; 2005; 11(5):404-11. PubMed ID: 16259871 [TBL] [Abstract][Full Text] [Related]
22. [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer]. Pilka R; Mícková I; Lubuský M; Dusková M; Rícánková M; Kudela M Ceska Gynekol; 2008 Jul; 73(4):222-7. PubMed ID: 18711961 [TBL] [Abstract][Full Text] [Related]
23. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients? Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882 [TBL] [Abstract][Full Text] [Related]
24. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. van Slooten HJ; Clahsen PC; van Dierendonck JH; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van de Velde CJ; van de Vijver MJ Br J Cancer; 1996 Jul; 74(1):78-85. PubMed ID: 8679463 [TBL] [Abstract][Full Text] [Related]
25. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366 [TBL] [Abstract][Full Text] [Related]
26. Analysis of CD40 expression in breast cancer and its relation to clinicopathological characteristics. Slobodova Z; Ehrmann J; Krejci V; Zapletalova J; Melichar B Neoplasma; 2011; 58(3):189-97. PubMed ID: 21391734 [TBL] [Abstract][Full Text] [Related]
27. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients. Aryandono T; Harijadi ; Ghozali A Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217 [TBL] [Abstract][Full Text] [Related]
28. Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: a pathway to metastatic progression in human breast cancer. Sierra A; Castellsagué X; Escobedo A; Lloveras B; García-Ramirez M; Moreno A; Fabra A Int J Cancer; 2000 Mar; 89(2):142-7. PubMed ID: 10754491 [TBL] [Abstract][Full Text] [Related]
29. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Callagy GM; Pharoah PD; Pinder SE; Hsu FD; Nielsen TO; Ragaz J; Ellis IO; Huntsman D; Caldas C Clin Cancer Res; 2006 Apr; 12(8):2468-75. PubMed ID: 16638854 [TBL] [Abstract][Full Text] [Related]
30. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. Pich A; Margaria E; Chiusa L J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127 [TBL] [Abstract][Full Text] [Related]
31. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas. Soslow RA; Carlson DL; Horenstein MG; Osborne MP Breast Cancer Res Treat; 2000 May; 61(2):161-70. PubMed ID: 10942102 [TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. With special reference to their prognostic significance in carcinoma. Tauchi K; Hori S; Itoh H; Osamura RY; Tokuda Y; Tajima T Virchows Arch A Pathol Anat Histopathol; 1989; 416(1):65-73. PubMed ID: 2573192 [TBL] [Abstract][Full Text] [Related]
33. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study. Wilbur DC; Barrows GH Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877 [TBL] [Abstract][Full Text] [Related]
34. Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status. Wang D; Konishi I; Koshiyama M; Mandai M; Nanbu Y; Ishikawa Y; Mori T; Fujii S Cancer; 1993 Nov; 72(9):2628-37. PubMed ID: 8104681 [TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors. Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944 [TBL] [Abstract][Full Text] [Related]
36. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662 [TBL] [Abstract][Full Text] [Related]
37. MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors. González-Vela MC; Garijo MF; Fernández F; Val-Bernal JF Histol Histopathol; 2001 Apr; 16(2):399-406. PubMed ID: 11332695 [TBL] [Abstract][Full Text] [Related]
38. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347 [TBL] [Abstract][Full Text] [Related]
39. Determination of cytosol c-erbB-2 protein in breast cancer by sandwich enzyme immunoassay. Imoto S; Ohkura H; Sugano K; Sasaki Y; Ito K; Igarashi T; Ohtsu T; Fujii H; Minami H; Hasebe T; Mukai K Jpn J Clin Oncol; 1998 Feb; 28(2):92-6. PubMed ID: 9544822 [TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of C-erbB-2 and hormone receptors' status in human benign and malignant breast lesions. Goussia A; Agnantis NJ; Athanassiadou S; Stefanou D Anticancer Res; 1995; 15(5B):2313-8. PubMed ID: 8572645 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]